

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities.*

*This announcement does not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States or any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The securities referred to herein will not be registered under the United States Securities Act of 1933, as amended (the “**Securities Act**”), and may not be offered or sold in the United States except pursuant to an exemption from, or a transaction not subject to, the registration requirements of the Securities Act. Any public offering of securities to be made in the United States will be made by means of a prospectus. Such prospectus will contain detailed information about the company making the offer and its management and financial statements. The Company does not intend to make any public offering of securities in the United States.*



## **LUYE PHARMA GROUP LTD.**

**绿叶制药集团有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 02186)**

### **PROPOSED SPIN-OFF AND SEPARATE LISTING OF BOAN BIOTECH ON THE MAIN BOARD OF THE STOCK EXCHANGE**

### **LISTING OF BOAN BIOTECH AND COMMENCEMENT OF DEALINGS IN THE H SHARES OF BOAN BIOTECH**

The Board is pleased to announce that following the completion of the Global Offering, listing of Boan Biotech on the Main Board of the Stock Exchange took place on 30 December 2022 and dealings in the H Shares of Boan Biotech on the Main Board of the Stock Exchange commenced at 9:00 a.m. on 30 December 2022.

## **INTRODUCTION**

Reference is made to the announcements of Luye Pharma Group Ltd. (the “**Company**”) in relation to the Proposed Spin-off of Boan Biotech (the “**Announcements**”). Unless otherwise defined, capitalized terms used in this announcement have the same meanings as those defined in the Announcements.

## **LISTING OF BOAN BIOTECH AND COMMENCEMENT OF DEALINGS**

The Stock Exchange has granted approval for the listing of, and permission to deal in, the H Shares of Boan Biotech on the Main Board of the Stock Exchange.

Following completion of the Global Offering (including the Preferential Offering), (i) listing of Boan Biotech on the Main Board of the Stock Exchange took place on 30 December 2022, and (ii) dealings in the H Shares of Boan Biotech on the Main Board of the Stock Exchange commenced at 9:00 a.m. on 30 December 2022. The H Shares of Boan Biotech are traded in board lots of 200 shares each and the stock code is 6955.

Upon completion of the Global Offering (including the Preferential Offering), the Company, through its wholly-owned subsidiaries, indirectly controls in aggregate approximately 70.81% of the total issued share capital of Boan Biotech (assuming that the Over-allotment Option is not exercised).

By Order of the Board  
**LUYE PHARMA GROUP LTD.**  
**Liu Dian Bo**  
*Chairman*

Hong Kong, 30 December 2022

*As at the date of this announcement, the executive directors of the Company are Mr. LIU Dian Bo, Mr. YANG Rong Bing, Mr. YUAN Hui Xian and Ms. ZHU Yuan Yuan; the non-executive Directors of the Company are Mr. SONG Rui Lin and Mr. SUN Xin; and the independent non-executive directors of the Company are Mr. ZHANG Hua Qiao, Professor LO Yuk Lam, Mr. LEUNG Man Kit and Mr. CHOY Sze Chung Jojo.*